These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 21861932)
21. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy. Miettinen S; Ylikomi T Anticancer Drugs; 2009 Aug; 20(7):589-600. PubMed ID: 19491654 [TBL] [Abstract][Full Text] [Related]
22. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Gregory-Bass RC; Olatinwo M; Xu W; Matthews R; Stiles JK; Thomas K; Liu D; Tsang B; Thompson WE Int J Cancer; 2008 May; 122(9):1923-30. PubMed ID: 18183577 [TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876 [TBL] [Abstract][Full Text] [Related]
24. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. Narendrula R; Mispel-Beyer K; Guo B; Parissenti AM; Pritzker LB; Pritzker K; Masilamani T; Wang X; Lannér C BMC Cancer; 2016 Feb; 16():146. PubMed ID: 26911141 [TBL] [Abstract][Full Text] [Related]
25. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Tai CK; Wang W; Lai YH; Logg CR; Parker WB; Li YF; Hong JS; Sorscher EJ; Chen TC; Kasahara N Cancer Gene Ther; 2010 Sep; 17(9):614-23. PubMed ID: 20467451 [TBL] [Abstract][Full Text] [Related]
28. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells. Sun X; Lou LG; Sui DH; Wu XH Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132 [TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Parker WB; Allan PW; Hassan AE; Secrist JA; Sorscher EJ; Waud WR Cancer Gene Ther; 2003 Jan; 10(1):23-9. PubMed ID: 12489025 [TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors. Fu W; Lan H; Li S; Han X; Gao T; Ren D Cancer Gene Ther; 2008 Jul; 15(7):474-84. PubMed ID: 18437183 [TBL] [Abstract][Full Text] [Related]
31. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
32. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Bharara S; Sorscher EJ; Gillespie GY; Lindsey JR; Hong JS; Curlee KV; Allan PW; Gadi VK; Alexander SA; Secrist JA; Parker WB; Waud WR Hum Gene Ther; 2005 Mar; 16(3):339-47. PubMed ID: 15812229 [TBL] [Abstract][Full Text] [Related]
33. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938 [TBL] [Abstract][Full Text] [Related]
35. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Parker WB; King SA; Allan PW; Bennett LL; Secrist JA; Montgomery JA; Gilbert KS; Waud WR; Wells AH; Gillespie GY; Sorscher EJ Hum Gene Ther; 1997 Sep; 8(14):1637-44. PubMed ID: 9322865 [TBL] [Abstract][Full Text] [Related]
36. Suicide gene/prodrug therapy using salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 2'-deoxyriboside in murine mammary carcinoma 4T1 model. Fu W; Lan H; Liang S; Gao T; Ren D Cancer Sci; 2008 Jun; 99(6):1172-9. PubMed ID: 18429958 [TBL] [Abstract][Full Text] [Related]
37. Metformin and epithelial ovarian cancer therapeutics. Patel S; Kumar L; Singh N Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765 [TBL] [Abstract][Full Text] [Related]
38. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Mohr L; Shankara S; Yoon SK; Krohne TU; Geissler M; Roberts B; Blum HE; Wands JR Hepatology; 2000 Mar; 31(3):606-14. PubMed ID: 10706550 [TBL] [Abstract][Full Text] [Related]
39. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy. Xie X; Guo J; Kong Y; Xie GX; Li L; Lv N; Xiao X; Tang J; Wang X; Liu P; Yang M; Xie Z; Wei W; Spencer DM; Xie X J Gene Med; 2011 Dec; 13(12):680-91. PubMed ID: 22009763 [TBL] [Abstract][Full Text] [Related]
40. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. Thibault B; Jean-Claude B J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]